Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Allogeneic hematopoietic stem cell transplantation is increasingly used as treatment for patients with life-threatening blood diseases. Its curative potential is largely based on immune-mediated graft-versus-leukemia effects caused by donor T cells contained in the graft. Unfortunately, donor T cells are also the cause of graft-versus-host disease. The vast majority of human leukocyte antigen-matched allogeneic hematopoietic stem cell transplants are nowadays carried out with peripheral blood stem cells as the stem cell source. In comparison with bone marrows, peripheral blood stem cells contain more hematopoietic stem/progenitor cells but also one log more T cells. Consequently, the use of peripheral blood stem cells instead of bone marrow has been associated with faster hematologic recovery and a lower risk of relapse in patients with advanced disease, but also with a higher incidence of chronic graft-versus-host disease. These observations have been the basis for several studies aimed at assessing the impact of immunoregulation with anti-thymocyte globulin on transplantation outcomes in patients given human leukocyte antigen-matched peripheral blood stem cells from related or unrelated donors. After a brief introduction on anti-thymocyte globulin, this article reviews recent studies assessing the impact of anti-thymocyte globulin on transplantation outcomes in patients given peripheral blood stem cells from human leukocyte antigen-matched related or unrelated donors as well as in recipients of grafts from human leukocyte antigen haploidentical donors.

[1]  P. Chevallier,et al.  Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire , 2016, Transplantation.

[2]  M. Labopin,et al.  Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT , 2016, Journal of Hematology & Oncology.

[3]  T. Panzarella,et al.  Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. , 2016, The Lancet. Oncology.

[4]  L. Luznik,et al.  Modern approaches to HLA-haploidentical blood or marrow transplantation. , 2016, Nature Reviews Clinical Oncology.

[5]  J. Esteve,et al.  Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT , 2016, Haematologica.

[6]  Giuseppe Milone,et al.  Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. , 2016, The New England journal of medicine.

[7]  A. Nagler,et al.  Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  F. Baron,et al.  Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets , 2015, Oncotarget.

[9]  A. Gennery,et al.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015 , 2015, Bone Marrow Transplantation.

[10]  C. Lengerke,et al.  Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation , 2015, Bone Marrow Transplantation.

[11]  F. Baron,et al.  Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation , 2015, PloS one.

[12]  M. Mohty,et al.  Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  Arnon Nagler,et al.  The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation , 2015, Haematologica.

[14]  F. Baron,et al.  Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning , 2015, Clinical Cancer Research.

[15]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[16]  F. Baron,et al.  Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society , 2014, Journal of Hematology & Oncology.

[17]  A. Gennery,et al.  Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants , 2015, Bone Marrow Transplantation.

[18]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  A. Deol,et al.  Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT , 2015, Bone Marrow Transplantation.

[20]  G. Rosner,et al.  Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. , 2014, Blood.

[21]  N. Kröger,et al.  Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy) , 2014 .

[22]  F. Baron,et al.  Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: A Phase II Randomized Study from the Belgian Hematological Society , 2014 .

[23]  Yu-Hong Chen,et al.  Who is the best donor for a related HLA haplotype-mismatched transplant? , 2014, Blood.

[24]  C. Griffiths,et al.  High serum level of antithymocyte globulin immediately before graft infusion is associated with a low likelihood of chronic, but not acute, graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  C. Cancrini,et al.  HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. , 2014, Blood.

[26]  B. Falini,et al.  HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. , 2014, Blood.

[27]  J. Ritz,et al.  Current issues in chronic graft-versus-host disease. , 2014, Blood.

[28]  M. Battaglia,et al.  Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors , 2014, Leukemia.

[29]  L. Xu,et al.  Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial , 2014, Bone Marrow Transplantation.

[30]  C. Flowers,et al.  Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors , 2014, Bone Marrow Transplantation.

[31]  P. Delvenne,et al.  Infusion of clinical‐grade enriched regulatory T cells delays experimental xenogeneic graft‐versus‐host disease , 2013, Transfusion.

[32]  N. Kröger,et al.  Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation , 2014, Bone Marrow Transplantation.

[33]  O. Majdic,et al.  A Comprehensive and Quantitative Analysis of the Major Specificities in Rabbit Antithymocyte Globulin Preparations , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  F. Ciceri,et al.  Pharmacokinetics (PK) Study Of Antithymocyte Globulins Fresenius (ATG-F) Prior To Allogeneic Stem Cell Transplantation: Implications For Timing Of Graft and Early Adoptive Immunotherapy Infusions , 2013 .

[35]  P. Ljungman,et al.  A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors , 2013, Clinical transplantation.

[36]  H. Deeg,et al.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  H. Deeg,et al.  Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. , 2013, Tissue antigens.

[38]  R. Bouabdallah,et al.  Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft‐versus‐host disease in reduced‐intensity conditioning transplantation for hematologic diseases , 2013, Cancer.

[39]  D. Porter,et al.  Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect. , 2013, Annual review of medicine.

[40]  J. Storek,et al.  Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse , 2013, Bone Marrow Transplantation.

[41]  L. Bouzas,et al.  Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  F. Baron,et al.  Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation , 2012, Leukemia.

[43]  P. Westervelt,et al.  Peripheral-blood stem cells versus bone marrow from unrelated donors. , 2012, The New England journal of medicine.

[44]  D. Maloney,et al.  Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. , 2012, Cytotherapy.

[45]  M. Baccarani,et al.  Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis , 2012, Bone Marrow Transplantation.

[46]  Bruce R. Blazar,et al.  Advances in graft-versus-host disease biology and therapy , 2012, Nature Reviews Immunology.

[47]  Jian Cheng,et al.  Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  B. Esterni,et al.  The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT , 2012, Bone Marrow Transplantation.

[49]  O. Majdic,et al.  Assessment of Batch to Batch Variation in Polyclonal Antithymocyte Globulin Preparations , 2012, Transplantation.

[50]  A. Nagler,et al.  Anti-T Lymphocyte Globulin (ATG) Induces Generation of Regulatory T Cells, at Least Part of Them Express Activated CD44 , 2012, Journal of Clinical Immunology.

[51]  N. Young,et al.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. , 2011, The New England journal of medicine.

[52]  D. Porter,et al.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2011, Blood.

[53]  H. Einsele,et al.  Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. , 2011, Blood.

[54]  M. Sorror,et al.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  B. Kurland,et al.  Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. , 2011, Blood.

[56]  R. Porcher,et al.  The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation , 2010, Leukemia.

[57]  J. Storek,et al.  High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[58]  H. Einsele,et al.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. , 2009, The Lancet. Oncology.

[59]  M. Remberger,et al.  Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[60]  Brit B. Turnbull,et al.  TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. , 2009, Blood.

[61]  Asha B. Pillai,et al.  Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. , 2009, Blood.

[62]  Arnon Nagler,et al.  A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. , 2008, Blood.

[63]  J. Sierra,et al.  Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  P. Munson,et al.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. , 2007, Blood.

[65]  M. Mohty,et al.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond , 2007, Leukemia.

[66]  J. Klein,et al.  Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. , 2007, Blood.

[67]  G. Opelz,et al.  Antithymocyte Globulins Suppress Dendritic Cell Function by Multiple Mechanisms , 2007, Transplantation.

[68]  P. Bruzzi,et al.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[69]  H. Deeg,et al.  Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[70]  D. Bloch,et al.  Protective conditioning for acute graft-versus-host disease. , 2005, The New England journal of medicine.

[71]  R. Hills,et al.  Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  D. Blaise,et al.  Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation , 2005, Leukemia.

[73]  M. Sorror,et al.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[75]  M. Sorror,et al.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning , 2004 .

[76]  R. Storb,et al.  Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review , 2004, Springer Seminars in Immunopathology.

[77]  I. Joosten,et al.  Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors , 2004, Bone Marrow Transplantation.

[78]  A. Barrett,et al.  Review Articles (434 articles) , 2003 .

[79]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[80]  N. Kröger,et al.  ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML) , 2003, Bone Marrow Transplantation.

[81]  S. Lonial,et al.  Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[82]  M. Leffell,et al.  Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[83]  David Klatzmann,et al.  Immunoregulatory T Cells : New Therapeutics for Graft-Versus-Host Disease , 2002 .

[84]  R. Soiffer,et al.  The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. , 2001, Blood.

[85]  P. Bruzzi,et al.  Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). , 2001, Blood.

[86]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[87]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[88]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[89]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[90]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[91]  R. Storb,et al.  ANTIHUMAN THYMOCYTE GLOBULIN FOR PROPHYLAXIS OF GRAFT‐VERSUS-HOST DISEASE: A RANDOMIZED TRIAL IN PATIENTS WITH LEUKEMIA TREATED WITH HLA‐IDENTICAL SIBLING MARROW GRAFTS , 1979, Transplantation.

[92]  G. Bornkamm,et al.  Characterization of EBV‐genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non‐Hodgkin lymphoma , 1977, International journal of cancer.